AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3096723
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg kg‐1
Trial: 31148473
Drug: Simple Daily
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Daily Sweepstakes
Trial: 31148473
Drug: Wireless-enabled pill
RxNorm normalized name: Enablex Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless-enabled pill bottle and daily reminder messages
Trial: 26418007
Drug: Low contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low contrast volume group (0.75 ml/kg)
Trial: 26418007
Drug: Routine contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine contrast volume group (1.5 ml/kg)
Trial: 20646266
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy with antibiotics: hospital admission, supportive measures, and at least 48 hours of intravenous antibiotics switched to oral for a total duration of 10 days.
Trial: 20646266
Drug: Liberal strategy
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal strategy without antibiotics: admission only if needed on clinical grounds, supportive measures only.
Trial: 20646266
Drug: Both strategies
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both strategies (antibiotics and no antibiotics)
Trial: 12411537
Drug: CHO (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (1 g (kg body mass)(-1) glucose 75 min prior to exercise)
Trial: 30111065
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine combined with noninvasive ventilator therapy (Control group)
Trial: 27311495
Drug: Buprenorphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (5 μg/h, titrated to a maximum of 40 μg/h)
Trial: 24833354
Drug: VMP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMP plus siltuximab (11 mg/kg every 3 weeks)
Trial: 17594199
Drug: Neither drug
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither drug (5 patients)
Trial: 17594199
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (zidovudine plus TMP-SMX)
Trial: 12401599
Drug: Ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15 mg/kg, maximum 4 mg (Group 1)
Trial: 12401599
Drug: Dolasetron 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 0.5 mg/kg, maximum 25 mg (Group 2)
Trial: 10023504
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg i.v. clomipramine
Trial: 10023504
Drug: 10-week oral
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-week oral clomipramine
Trial: 10023504
Drug: 10-week oral
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-week oral fluvoxamine
Trial: 1955308
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg yohimbine per os 4 times a day for 3 weeks
Trial: 1955308
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg yohimbine per os
Trial: 29883769
Drug: Oral omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral omega-3 (ω3) supplementation
Trial: 24914003
Drug: Soapy water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soapy water (30 g powdered detergent in 1.5 L water)
Trial: 21993999
Drug: Electronic alerts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic alerts recommending performance of an electrocardiogram and administration of aspirin for high risk patients (FRS ≥ 10%)
Trial: 17324155
Drug: Low-dose doxycycline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose doxycycline (LDD) for 3 months
Trial: 9715839
Drug: Acute methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute methadone treatment
Trial: 9715839
Drug: Chronic methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic methadone treatment
Trial: 1107769
Drug: Alprenolol slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol slow-release formulation (Aptin Durules) 400-800 mg per day
Trial: 1107769
Drug: Alprenolol ordinary
RxNorm normalized name: alprenolol
DrugBank: Alprenolol (DB00866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol ordinary tablets (Aptin) 400 mg per day
Trial: 1107769
Drug: Alprenolol slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol slow-release formulation (Aptin Durules) double dosage
Trial: 31464960
Drug: DEX (1 μg·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX (1 μg·kg for 10 minutes, then adjusted to 0.2‐0.7 μg·kg·hour)
Trial: 31464960
Drug: DEX (0.5 μg·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX (0.5 μg·kg for 10 minutes, then adjusted to 0.2‐0.7 μg·kg·hour)
Trial: 31464960
Drug: Sufentanil (0.3 μg·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.3 μg·kg for 10 minutes, then adjusted to 0.2‐0.4 μg·kg·hour)
Trial: 24127952
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg vaginal progesterone daily until delivery
Trial: 18494605
Drug: Interleukin-10 (IL-10)
RxNorm normalized name: non-viral human interleukin-10 (IL-10) variant (IL-10var) encoding plasmid deoxyribonucleic acid (pDNA)
DrugBank: Interleukin-10 (DB12880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-10 (IL-10) concentrations > or = 37 pg/mL
Trial: 18494605
Drug: Total protein
RxNorm normalized name: Total Protein Reagent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total protein concentrations > or = 674 mg/L
Trial: 18494605
Drug: CSF WBC
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CSF WBC counts < or = 5 cells/microL (6 months after treatment)
Trial: 18494605
Drug: CSF WBC
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CSF WBC count > or = 8 cells/microL and LATEX/IgM end titer > or = 1:4 (12 months after treatment)
Trial: 18494605
Drug: CSF WBC
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CSF WBC count > or = 8 cells/microL and LATEX/IgM end titer > or = 1:4 (18 and 24 months after treatment)
Trial: 17002722
Drug: Mebendazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (500 mg single dose) plus iron supplements (60 mg elemental iron daily)
Trial: 16940835
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus iron supplements
Trial: 8966351
Drug: dehydrobenzperidol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dehydrobenzperidol (1.25 mg)
Trial: 8966351
Drug: placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (2 ml saline)
Trial: 1342886
Drug: Micronized, freeze-dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized, freeze-dried DP extract in powder (active therapy)
Trial: 1342886
Drug: Lactose capsules
RxNorm normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose capsules (placebo group)
Trial: 3871188
Drug: Prednisone 20
RxNorm normalized name: prednisone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 20 mg
Trial: 31798892
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (matched by age, sex, and treatment arm)
Trial: 22189593
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray (FP) 100 mcg twice daily as initial treatment with Fexofenadine hydrochloride tablet (FEX) 60 mg twice daily as additional treatment
Trial: 22189593
Drug: Fexofenadine hydrochloride
RxNorm normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride tablet (FEX) 60 mg twice daily as initial treatment with Fluticasone propionate nasal spray (FP) 100 mcg twice daily as additional treatment
Trial: 10511346
Drug: Combined estradiol‐progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined estradiol‐progestogen (2 mg estradiol + 0.5 mg trimegestone or 10 mg dydrogesterone)
Trial: 10511346
Drug: Unopposed estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unopposed estradiol (2 mg)
Trial: 31621936
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of any antiepileptic drug
Trial: 31621936
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of any antiepileptic drug in individuals with a history of suicidal behavior
Trial: 31621936
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of any antiepileptic drug in individuals without a history of suicidal behavior
Trial: 31621936
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of any antiepileptic drug in individuals with a familial predisposition to psychiatric disorders
Trial: 31621936
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of any antiepileptic drug in individuals without a familial predisposition to psychiatric disorders
Trial: 27672124
Drug: PF‐04236921 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04236921 10 mg
Trial: 27672124
Drug: PF‐04236921 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04236921 50 mg
Trial: 27672124
Drug: PF‐04236921 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04236921 200 mg
Trial: 23968157
Drug: CHF5074 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF5074 (600 mg/day)
Trial: 23968157
Drug: CHF5074 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF5074 (200 mg/day)
Trial: 23968157
Drug: CHF5074 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF5074 (400 mg/day)
Trial: 23968157
Drug: CHF5074 (dose-dependent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF5074 (dose-dependent)
Trial: 19142656
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (Cr) and Glycerol (Gly) supplementation (20 g Cr and 2 g Gly per kg body mass plus 2 l of water)
Trial: 16489526
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan (200 mg/m(2)) and autologous blood stem-cell support
Trial: 16489526
Drug: Cyclophosphamide (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (2-4 g/m(2)) and rhG-CSF
Trial: 9032543
Drug: Sabal serrulata
RxNorm normalized name: Sabal Serrulata
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabal serrulata extract IDS 89 (Strogen) 320 mg/capsule, 3 x 2 capsules daily for 3 months
Trial: 8495772
Drug: IVF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatment (one cycle)
Trial: 31786367
Drug: High vowel
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High vowel overlap training (e.g., EA, AI)
Trial: 31786367
Drug: Low vowel
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low vowel overlap training (e.g., EE, AI)
Trial: 28122649
Drug: L- and
RxNorm normalized name: Glycerol- and honey-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L- and MZ-enriched eggs
Trial: 15094102
Drug: Oral amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amino acid mixture (OAAM)
Trial: 11922397
Drug: Promethazine (PRM)
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Promethazine (PRM) 30 mg
Trial: 11922397
Drug: Levocetirizine (L-CTZ)
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocetirizine (L-CTZ) 5 mg
Trial: 11922397
Drug: Cetirizine (CTZ)
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine (CTZ) 10 mg
Trial: 11922397
Drug: Loratadine (LOR)
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine (LOR) 10 mg
Trial: 9517644
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 250 mg q.i.d.
Trial: 9517644
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 500 mg b.i.d.
Trial: 9517644
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 500 mg b.i.d. and metronidazole 400 mg b.i.d. for the first 2 wk
Trial: 16873325
Drug: Usual conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual conservative treatment (UT)
Trial: 16873325
Drug: Self-care treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-care treatment without splint therapy (UT)
Trial: 10672051
Drug: PCM-7 (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCM-7 (7 days of pantoprazole 40 mg bid, clarithromycin 500 mg bid, metronidazole 500 mg bid)
Trial: 10672051
Drug: PCM-14 m
RxNorm normalized name: M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCM-14 m (modified 14 day therapy with metronidazole only given for 10 days)
Trial: 9280742
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride 100 mg p.o. or i.m. for moderate to intense pain
Trial: 8149141
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg acyclovir orally four times daily during induction therapy
Trial: 3521240
Drug: Dipyrone 575
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 575 mg
Trial: 1626990
Drug: Tartrazine 50
RxNorm normalized name: tartrazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tartrazine 50 mg
Trial: 29498050
Drug: Granulocyte transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte transfusion therapy plus antimicrobials
Trial: 27687354
Drug: Flexed lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexed lateral position (L)
Trial: 24757084
Drug: Ivabradine (Iva)
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine (Iva) 5 mg BID
Trial: 24757084
Drug: Atenolol (Aten)
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol (Aten) 12.5 mg BID
Trial: 22493914
Drug: Aconite cake-separated
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aconite cake-separated moxibustion therapy with acupoints (Danzhong (CV 17), Zhongwan (CV 12), Guanyuan (CV 4), Dazhui (GV 14), Shenshu (BL 23), Mingmen (GV 4)) and oral administration of 25 microg Euthyrox everyday
Trial: 22493914
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 25 microg Euthyrox everyday
Trial: 12826990
Drug: Acamprosate 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate 2 g/day
Trial: 12826990
Drug: Acamprosate 3
RxNorm normalized name: acamprosate 333 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate 3 g/day
Trial: 12826990
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Naltrexone and Acamprosate)
Trial: 12826990
Drug: Naltrexone and
RxNorm normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone and Acamprosate (both alone and in combination)
Trial: 12826990
Drug: Combined medications
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined medications
Trial: 10821210
Drug: Alcohol pre-load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol pre-load (9 oz or 270 ml of beer)
Trial: 1710922
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with eight cycles of MOPP
Trial: 1710922
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MOPP and ABVD
Trial: 1710922
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (including both arms)
Trial: 1710922
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of relapsed patients
Trial: 21942692
Drug: First-line antiretroviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line antiretroviral (ARV) treatment
Trial: 17559147
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy with elevated serum HER-2/neu levels (>15 ng/mL) before treatment
Trial: 17559147
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy with elevated serum HER-2/neu levels at 2 months
Trial: 17559147
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy with changes in HER-2/neu levels between baseline and 2 months
Trial: 17559147
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy with >or=20% increase of serum HER-2/neu
Trial: 17559147
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy with kinetics of serum HER-2/neu
Trial: 17559147
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy with low baseline serum levels of EGFR (<45 ng/mL)
Trial: 17559147
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy with low baseline serum levels of EGFR
Trial: 11955464
Drug: Yohimbine (.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (.4 mg/kg, IV)
Trial: 9484152
Drug: MOD onlay
RxNorm normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: MOD onlay preparation
Trial: 3926042
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of morphine
Trial: 20297613
Drug: Oxycodone/acetaminophen (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/acetaminophen (5 mg/325 mg, titrated for pain relief)
Trial: 20297613
Drug: Oxycodone/acetaminophen (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/acetaminophen (mean daily dose 13.8 mg/720.4 mg)
Trial: 18685961
Drug: Intrathecal thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal thoracic analgesia (ITA) with levobupivacaine 0.25%, at 0.5-0.7 ml/h, and a single bolus of morphine 0.15 mg
Trial: 18685961
Drug: Epidural thoracic
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural thoracic analgesia (ETA) with levobupivacaine 0.25% 4-6 ml/h and a single bolus of epidural morphine 2-3 mg
Trial: 15741443
Drug: Fluticasone 500
RxNorm normalized name: FLUTICASONE 500MCG/SALMETEROL 50MCG INHL,ORAL,DISKUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 500 mug twice daily
Trial: 12515837
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (6 weekly sessions)
Trial: 12515837
Drug: Supportive psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive psychotherapy (6 weekly sessions)
Trial: 10916110
Drug: Hydrosoluble vitamins
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrosoluble vitamins (DiaVite) supplementation once daily by mouth
Trial: 10916110
Drug: Intravenous folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous folic acid (10 mg posthemodialysis, 30 mg per week) in addition to DiaVite